Press Release / Media Release
Zydus Cadila's EBIDTA up by 68% in Q2.14-11-2017
Financial Results For The Quarter / Half Year Ended On September 30, 2017.
Results with Limited Review Report of the Statutory Auditors.14-11-2017
Clarifies on News Item
The Exchange had sought clarification from the company with respect to news appearing in www.livemint.com on November 10, 2017 titled "Zydus Cadila, Intas under scanner for launching hypertension drug without permit"The company response is enclosed.13-11-2017
Zydus gets Mexico approval for diabetes drugs
Cadila Healthcare has said in a statement that the Mexican regulatory authority COFEPRIS has granted marketing approval to commercialise Lipaglyn (Saroglitazar magnesium) in Mexico. The drug is used...12-11-2017
Cadila Healthcare gets Mexican regulatory nod to market Lipaglyn drug
Drug firm Cadila Healthcare on Friday said it has received approval from the Mexican regulatory authority to market Lipaglyn (Saroglitazar Magnesium) used for the treatment of dyslipidemia in...10-11-2017
Clarification sought from Cadila Healthcare Ltd
The Exchange has sought clarification from Cadila Healthcare Ltd with respect to news article appearing on www.livemint.com on November 10, 2017 titled "Zydus Cadila, Intas under scanner for launching hypertension drug without permit".The reply is awaited.10-11-2017
Zydus announces regulatory approval of Lipaglyn (Saroglitazar Magnesium) in Mexico
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated November 10, 2017 titled "Zydus announces regulatory approval of Lipaglyn (Saroglitazar Magnesium) in Mexico".10-11-2017
Nesher Pharma gets USFDA nod to market ADHD tablets
Cadila Healthcare today said that Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the US health regulator to market Dextroamphetamine Sulfate and...02-11-2017
Press Release / Media Release
Zydus' Nesher Pharmaceuticals gets USFDA final approval for Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets02-11-2017
Analyst / Investor Meet - Intimation
Pursuant to regulation 30 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015, we hereby inform that the Company has planned investor interaction through a conference call on November 14, 2017 at 4:00 p.m., post announcement of unaudited financial results for the quarter / half year ended on September 30, 2017.02-11-2017